Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm (NASDAQ: IRTC) reported Q1 2026 results: revenue $199.4M (+25.7% YoY), gross margin 70.9% (+210 bps), and adjusted EBITDA $14.1M (7.1% margin). Unrestricted cash and marketable securities totaled $549.6M at March 31, 2026.
The company raised 2026 guidance to $875M–$885M revenue and adjusted EBITDA margin 12%–13%, citing volume-led growth, gross margin expansion, and continued investments in AI-enabled cardiac solutions.
iRhythm Holdings (NASDAQ:IRTC) will present at the Bank of America Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 9:20 a.m. PT / 12:20 p.m. ET. The management presentation will be available via live webcast and archived replay on the company’s investor website.
Investors can access the presentation in the Events & Presentations section at investors.irhythmtech.com.
iRhythm (NASDAQ:IRTC) reported real-world analyses presented at HRS 2026 showing short-duration 24–48-hour Holter monitoring misses a substantial portion of arrhythmias compared with up to 14 days of continuous Zio ambulatory ECG monitoring.
Key findings: post-ablation AF recurrence was 21% overall with 26% of first recurrences detected after 48 hours, and pregnancy monitoring found arrhythmias in 37.7% of patients with 13.6% clinically significant—most detected after 48 hours.
iRhythm Holdings (NASDAQ:IRTC) will report first quarter 2026 financial results after market close on Thursday, April 30, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live and archived webcast available.
Investors may access the webcast via the Quarterly Results section of the company investor website at investors.irhythmtech.com.
iRhythm (NASDAQ: IRTC) reported retrospective ACC.26 analyses showing a high prevalence of clinically actionable arrhythmias across cardiometabolic and kidney-metabolic (CKM) populations and launched iRhythm Academy clinician education. Key findings: 48% arrhythmia prevalence in CKD, 47% with both diabetes+CKD, AF prevalence rose from 4.5% to 6.5% with severe obesity, adjusted AF odds ratio 2.8.
Company highlighted AI scaling in cardiology and announced a Spanish-language update to the MyZio mobile app.
iRhythm (NASDAQ: IRTC) appointed Jason Patten to its Board of Directors, effective March 12, 2026. The company said Patten brings decades of strategic healthcare leadership to support scaling toward profitability and advancing its AI-enabled, proactive care platform.
Management highlights expectations for Patten to help expand primary care access, strengthen strategic partnerships, and drive disciplined growth as iRhythm pursues a "billion-dollar platform" grounded in clinical excellence.
iRhythm (NASDAQ: IRTC) reported strong Q4 and full-year 2025 results with revenue growth, margin expansion, and improved profitability. Q4 revenue was $208.9M (+27.1% YoY); full-year revenue was $747.1M (+26.2% YoY). Q4 GAAP net income was $5.6M; FY adjusted EBITDA was $68.9M. Cash and marketable securities totaled $583.8M. The company provided 2026 guidance of $870M–$880M revenue and adjusted EBITDA margin of 11.5%–12.5%.
Management cited volume growth across US core, innovative channels, and international markets, plus first-year positive free cash flow of $34.5M.
iRhythm Holdings (NASDAQ: IRTC) will release fourth quarter and full year 2025 financial results after market close on February 19, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET with a live and archived webcast available on the company’s investor site.
iRhythm (NASDAQ:IRTC) provided preliminary Q4 2025 highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. The company expects full‑year 2025 revenue to exceed the high end of prior guidance of $740 million, driven by record revenue unit volume in Q4 2025. For full‑year 2026, iRhythm projects revenue of $870–$880 million (approximately 17%–18% YoY) and an adjusted EBITDA margin of ~11.5%–12.5%. Management cited clinical evidence from >1.4 million patients supporting Zio long‑term continuous monitoring and noted free cash flow positivity in 2025. Management presented on Jan 12, 2026 at 8:15 AM PT; a live and archived webcast is available on the company investor site.
iRhythm Technologies (NASDAQ:IRTC) will present at the 44th Annual J.P. Morgan Healthcare Conference.
Management is scheduled to present on Monday, January 12, 2026 at 8:15 a.m. PT / 11:15 a.m. ET. A live and archived webcast will be available in the Events and Presentations section of the company investor website at investors.irhythmtech.com.